Rigel Pharmaceuticals
RIGL
99 hedge funds and large institutions have $357M invested in Rigel Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 35 increasing their positions, 30 reducing their positions, and 16 closing their positions.
70% more capital invested
Capital invested by funds: $210M → $357M (+$146M)
41% more call options, than puts
Call options by funds: $148K | Put options by funds: $105K
17% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 30
0.09% less ownership
Funds ownership: 8.92% → 8.83% (-0.09%)
7% less funds holding
Funds holding: 107 → 99 (-8)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
Top Buyers
| 1 |
BlackRock
New York
|
+$25.8M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$23.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.93M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$8.36M |
| 5 |
Millennium Management
New York
|
+$3.76M |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$7.32M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.21M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.36M |
| 4 |
Goldman Sachs
New York
|
-$1.08M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$1.03M |
RIGL Hedge Fund Activity: Q1 2017 in Review
99 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q1 2017, worth a combined $357M — up 70% from $210M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of RIGL and 14 opened new positions — a net loss of 2 holders — while 30 trimmed existing stakes and 35 added.
The largest buyer was BlackRock, adding an estimated $25.8M. The largest seller was Citadel Advisors, cutting an estimated $7.32M.
- 99 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q1 2017, down from 107 in Q4 2016.
- Funds reported $357M of Rigel Pharmaceuticals stock for Q1 2017, up 70% quarter-over-quarter.
- 14 funds opened new Rigel Pharmaceuticals positions in Q1 2017 and 16 closed out, a net change of -2 holders.
- The largest Rigel Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $25.8M added.
- The largest Rigel Pharmaceuticals seller in Q1 2017 was Citadel Advisors, an estimated $7.32M sold.
Based on aggregated 13F filings for Q1 2017.